These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37368200)

  • 21. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
    Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
    [No Abstract]   [Full Text] [Related]  

  • 22. MRD in ALL: Optimization and Innovations.
    Pierce E; Mautner B; Mort J; Blewett A; Morris A; Keng M; El Chaer F
    Curr Hematol Malig Rep; 2022 Aug; 17(4):69-81. PubMed ID: 35616771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemia.
    Ceppi F; Rizzati F; Colombini A; Conter V; Cazzaniga G
    Expert Rev Hematol; 2021 Sep; 14(9):795-807. PubMed ID: 34374613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
    Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
    Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
    Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
    Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
    Gaipa G; Basso G; Biondi A; Campana D
    Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.
    Pemmaraju N; Kantarjian H; Jorgensen JL; Jabbour E; Jain N; Thomas D; O'Brien S; Wang X; Huang X; Wang SA; Konopleva M; Konoplev S; Kadia T; Garris R; Pierce S; Garcia-Manero G; Cortes J; Ravandi F
    Am J Hematol; 2017 Mar; 92(3):279-285. PubMed ID: 28052371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
    Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
    Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia.
    Eveillard M; Robillard N; Arnoux I; Garand R; Rialland F; Thomas C; Strullu M; Michel G; Béné MC; Fossat C; Loosveld M
    Hematol Oncol; 2017 Jun; 35(2):237-243. PubMed ID: 26449287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation.
    Zhao X; Zhao X; Chen H; Qin Y; Xu L; Zhang X; Liu K; Huang X; Chang YJ
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1936-1943. PubMed ID: 29572111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
    Locatelli F; Eckert C; Hrusak O; Buldini B; Sartor M; Zugmaier G; Zeng Y; Pilankar D; Morris J; von Stackelberg A
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29715. PubMed ID: 35482538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Minimal Residual Disease by a Single-Tube 8-Color Flow Cytometric Analysis With Clinical Outcome in Adult B-Cell Acute Lymphoblastic Leukemia: A Real-World Study Based on 486 Patients.
    Liao H; Jiang N; Yang Y; Zhang X; Chen J; Lai H; Zheng Q
    Arch Pathol Lab Med; 2023 Oct; 147(10):1186-1195. PubMed ID: 36508349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Minimal Residual Disease Detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia.
    Algamal RA; Abu Samra NK; Ellashery RA; Abd-EL-Hameed SAE; Shahin DA
    Asian Pac J Cancer Prev; 2023 Oct; 24(10):3577-3584. PubMed ID: 37898866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
    Tembhare PR; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Panda D; Patkar NV; Narula G; Girase K; Verma S; Sanyal M; Sriram HN; Banavali S; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2021 Jul; 100(4):421-433. PubMed ID: 32812702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flow cell sorting followed by PCR-based clonality testing may assist in questionable diagnosis and monitoring of acute lymphoblastic leukemia.
    Semchenkova A; Zhogov V; Zakharova E; Mikhailova E; Illarionova O; Larin S; Novichkova G; Karachunskiy A; Maschan M; Popov A
    Int J Lab Hematol; 2023 Aug; 45(4):506-515. PubMed ID: 36871952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
    Yu CH; Jou ST; Su YH; Coustan-Smith E; Wu G; Cheng CN; Lu MY; Lin KH; Wu KH; Chen SH; Huang FL; Chang HH; Wang JL; Yen HJ; Li MJ; Chou SW; Ho WL; Liu YL; Chang CC; Lin ZS; Lin CY; Chen HY; Ni YL; Lin DT; Lin SW; Yang JJ; Ni YH; Pui CH; Yu SL; Yang YL
    Cancer; 2023 Mar; 129(5):790-802. PubMed ID: 36537587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
    Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
    Scrideli CA; Assumpção JG; Ganazza MA; Araújo M; Toledo SR; Lee ML; Delbuono E; Petrilli AS; Queiróz RP; Biondi A; Viana MB; Yunes JA; Brandalise SR; Tone LG
    Haematologica; 2009 Jun; 94(6):781-9. PubMed ID: 19483156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between a 10-color flow cytometric measurable residual disease (MRD) analysis and molecular MRD in adult B-acute lymphoblastic leukemia.
    Singh J; Gorniak M; Grigoriadis G; Westerman D; McBean M; Venn N; Law T; Sutton R; Morgan S; Fleming S
    Cytometry B Clin Cytom; 2022 Mar; 102(2):115-122. PubMed ID: 34806309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.